This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

EU Pharmaceutical Law Forum
Hybrid Event | 23 - 25 May 2023
Steigenberger Wiltcher's, Brussels

Oliver Kronenberg
General Counsel at CSL Vifor


Dr Oliver P. Kronenberg has over 25 years’ experience both in law firms and in-house, of which 19 years has been with people management responsibility. He amasses 18 years in the international pharmaceutical industry, covering matters related to originator products, medical devices, consumer health and logistics, and retail. He joined his current employer Vifor Pharma as head of legal and compliance in 2008. In January 2013 he was promoted to group general counsel of Galenica, Vifor Pharma’s parent company. Following the split of the Galenica Group in April 2017, he moved back to Vifor Pharma to become their group general counsel and member of the executive committee. Prior to his arrival, the legal work was done out of the holding company Galenica, and Dr Kronenberg has since standardised agreements and processes. Some of the accomplishments achieved during his time at Vifor Pharma include the establishment of Vifor Pharma’s legal, IP and compliance department, being the sole lawyer in October 2008, and growing to a 32-strong team in 2022, in conjunction with Vifor Pharma Group’s substantial growth to being today’s third biggest life science company in Switzerland. He has managed the negotiations of the US$ 12bn acquisition of Vifor Pharma by CSL group and the US$1.6bn acquisition of Relypsa by Vifor Pharma, both including respective antitrust and SEC filings in the US and elsewhere, and the IPO of Galenica Santé in April 2017 – the second biggest IPO worldwide in 2017 raising just over CHF2bn. He is also the lead counsel within Vifor Pharma towards the EU Commission in their antitrust investigation for a potential abuse of a dominant position.

Agenda Sessions

  • DUAL DIALOGUE: Success Factors for Licensing Life Science Deals


Speakers at this event